News
We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...
In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene therapy ...
Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 4.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, ...
Sarepta Therapeutics is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has ...
Sarepta Therapeutics (SRPT 3.29%), a biotechnology company developing RNA-based medicines, gene-edited products, and gene therapies for rare diseases, ...
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 4.9% in that time frame, outperforming the S&P 500.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results